

U.S.S.N.: 09/766,362

Filed: January 19, 2001

AMENDMENT AND RESPONSE TO OFFICE ACTION

In the claims

1. (currently amended) (three times amended) A composition for the nasal administration of a drug in a dry powder form ~~having an average particle size of between 10 and 20 microns, in a dosage formulation suitable~~ for administration to the nasal region,

201
the dry powder form comprising microparticles ~~which comprise~~ having an average particle size of between 10 and 20 microns and consisting essentially of the drug and a material an excipient selected from the group consisting of diketopiperazines and synthetic polymers selected from the group consisting of: poly(hydroxy acids), ~~poly(lactic acid), poly(glycolic acid)~~ and copolymers thereof, polyanhydrides, polyesters, polyorthoesters, polyamides, polycarbonates, polyalkylenes ~~including polyethylene and polypropylene~~, poly(ethylene glycol), poly(ethylene oxide), poly(ethylene terephthalate), polyvinyl alcohols, polyvinyl ethers, polyvinyl esters, polyvinyl halides, polyvinylpyrrolidone, poly vinyl chloride, polystyrene, polysiloxanes, polymers of acrylic and methacrylic acids ~~including poly(methyl methacrylate), poly(ethyl methacrylate), poly(butyl methacrylate), poly(isobutyl methacrylate), poly(hexyl methacrylate), poly(isodecyl methacrylate), poly(lauryl methacrylate), poly(phenyl methacrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), poly(octadecyl acrylate)~~, polyurethanes and co-polymers thereof, celluloses ~~including alkyl cellulose, hydroxyalkyl celluloses, cellulose ethers, cellulose esters, nitro celluloses, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxy propyl methyl cellulose, hydroxybutyl methyl cellulose, cellulose acetate, cellulose propionate, cellulose acetate butyrate, cellulose acetate phthalate, carboxylethyl cellulose, cellulose triacetate, and cellulose sulphate~~

U.S.S.N.: 09/766,362

Filed: January 19, 2001

AMENDMENT AND RESPONSE TO OFFICE ACTION

~~sodium salt, poly(butic acid), poly(valeric acid), poly(lactide-co-caprolactone), zein, prolamines and hydrophobic proteins, copolymers and mixtures thereof.~~

2. (original) The composition of claim 1 wherein the drug is selected from the group consisting of antihistamine, vasoconstrictors, antiinflammatories and analgesics.

3. (original) The composition of claim 2 wherein the antihistamine is selected from the group consisting of chlorpheniramine and azelastine.

4. (original) The composition of claim 1 wherein the drug is formulated in a polymeric carrier.

5. (original) The composition of claim 1 wherein the drug is formulated in a diketopiperazine formulation.

Please cancel claim 6. (cancelled) The composition of claim 1 wherein the dry powder formulation consists essentially of drug.

7. (currently amended) (three times amended) A drug delivery device for nasal administration comprising

a drug in a dry powder form ~~having an average particle size of between 10 and 20 microns~~; in a dosage formulation for administration to the nasal region, and

a device for delivering a measured dose of the drug to the nasal mucosa,

wherein the dry powder form comprises microparticles ~~which comprise~~ having an average particle size of between 10 and 20 microns and consisting essentially of the drug and a material an excipient selected from the group consisting of diketopiperazines and synthetic polymers selected from the group consisting of; poly(hydroxy acids), ~~poly(lactic acid), poly(glycolic acid)~~ and copolymers thereof, polyanhydrides, polyesters, polyorthoesters, polyamides, polycarbonates, polyalkylenes ~~including polyethylene and polypropylene,~~

U.S.S.N.: 09/766,362

Filed: January 19, 2001

AMENDMENT AND RESPONSE TO OFFICE ACTION

201
cont.

poly(ethylene glycol), poly(ethylene oxide), poly(ethylene terephthalate), polyvinyl alcohols, polyvinyl ethers, polyvinyl esters, polyvinyl halides, polyvinylpyrrolidone, poly vinyl chloride, polystyrene, polysiloxanes, polymers of acrylic and methacrylic acids, including poly(methyl methacrylate), poly(ethyl methacrylate), poly(butylmethacrylate), poly(isobutyl methacrylate), poly(hexylmethacrylate), poly(isodecyl methacrylate), poly(lauryl methacrylate), poly(phenyl methacrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), poly(octadecyl acrylate), polyurethanes and co-polymers thereof, celluloses ~~including alkyl cellulose, hydroxyalkyl celluloses, cellulose ethers, cellulose esters, nitro celluloses, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxy-propyl methyl cellulose, hydroxybutyl methyl cellulose, cellulose acetate, cellulose propionate, cellulose acetate butyrate, cellulose acetate phthalate, carboxylethyl cellulose, cellulose triacetate, and cellulose sulphate sodium salt~~, poly(butic acid), poly(valeric acid), poly(lactide-co-caprolactone), ~~zein, prolamines and hydrophobic proteins~~, copolymers and mixtures thereof.

8. (original) The device of claim 7 wherein the device is a nasal insufflator.

9. (original) The device of claim 7 wherein the drug is selected from the group consisting of antihistamine, vasoconstrictors, antiinflammatories and analgesics.

10. (original) The device of claim 7 wherein the antihistamine is selected from the group consisting of chlorpheniramine and azelastine.

11. (original) The device of claim 7 wherein the drug is formulated in a polymeric carrier.

12. (original) The device of claim 7 wherein the drug is formulated in a diketopiperazine formulation.

U.S.S.N.: 09/766,362

Filed: January 19, 2001

AMENDMENT AND RESPONSE TO OFFICE ACTION

Please cancel claim 13. (cancelled) The device of claim 7 wherein the dry powder formulation consists essentially of drug.

14. (currently amended) (three times amended) A method of administering a drug to the nasal region of a patient in need thereof, comprising nasally administering a dry powder ~~form of~~ a drug ~~having an average particle size of between 10 and 20 microns, in a dosage formulation~~ suitable for nasal administration,

201
cont.

wherein the dry powder form comprises microparticles ~~which comprise~~ having an average particle size of between 10 and 20 microns and consisting essentially of the drug and a ~~material~~ an excipient selected from the group consisting of diketopiperazines and synthetic polymers selected from the group consisting of: poly(hydroxy acids), ~~poly(lactic acid),~~ poly(glycolic acid) and copolymers thereof, polyanhydrides, polyesters, polyorthoesters, polyamides, polycarbonates, polyalkylenes ~~including polyethylene and polypropylene,~~ poly(ethylene glycol), poly(ethylene oxide), poly(ethylene terephthalate), polyvinyl alcohols, polyvinyl ethers, polyvinyl esters, polyvinyl halides, polyvinylpyrrolidone, poly vinyl chloride, polystyrene, polysiloxanes, polymers of acrylic and methacrylic acids ~~including poly(methyl methacrylate), poly(ethyl methacrylate), poly(butyl methacrylate), poly(isobutyl methacrylate), poly(hexyl methacrylate), poly(isodecyl methacrylate), poly(lauryl methacrylate), poly(phenyl methacrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), poly(octadecyl acrylate),~~ polyurethanes and co-polymers thereof, celluloses, ~~including alkyl cellulose, hydroxyalkyl celluloses, cellulose ethers, cellulose esters, nitro celluloses, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxy propyl methyl cellulose, hydroxybutyl methyl cellulose, cellulose acetate, cellulose propionate, cellulose acetate butyrate, cellulose acetate phthalate, carboxylethyl cellulose, cellulose triacetate, and cellulose sulphate~~

U.S.S.N.: 09/766,362

Filed: January 19, 2001

AMENDMENT AND RESPONSE TO OFFICE ACTION

~~sodium salt, poly(butic acid), poly(valeric acid), poly(lactide-co-caprolactone), zein, prolamines~~
~~and hydrophobic proteins, copolymers and mixtures thereof.~~

15. (original) The method of claim 14 wherein the drug is selected from the group consisting of antihistamine, vasoconstrictors, antiinflammatories and analgesics.

201
cancel
16. (original) The method of claim 14 wherein the antihistamine is selected from the group consisting of chlorpheniramine and azelastine.

17. (original) The method of claim 14 wherein the drug is formulated in a polymeric carrier.

18. (original) The method of claim 14 wherein the drug is formulated in a diketopiperazine formulation.

Please cancel claim 19. (cancelled) The method of claim 14 wherein the dry powder formulation consists essentially of drug.
